In the version of this article initially published, the IA-2 545-562 peptide identified as a target of a T cell clone was mislabeled as the native version of the peptide. The T cell clone responded to a modified version of the peptide with glutamine-to-glutamic-acid deaminations at positions 548, 551 and 556. The sentence, "From donor T1D.7, a CD4 + T cell clone recognized an IA-2 peptide with three glutamine-to-glutamic-acid deaminations (IA-2 545-562(Q-G548,551,556)
In the version of this article initially published, the IA-2 545-562 peptide identified as a target of a T cell clone was mislabeled as the native version of the peptide. The T cell clone responded to a modified version of the peptide with glutamine-to-glutamic-acid deaminations at positions 548, 551 and 556. The sentence, "From donor T1D.7, a CD4 + T cell clone recognized an IA-2 peptide with three glutamine-to-glutamic-acid deaminations (IA-2 545-562(Q-G548,551,556) ; Fig. 2e )" has been added on p.1484 to reflect this. The relevant text has also been edited in the main text on p.1483; in Figure In the version of this article published in print, Jeffrey A Bluestone was missing an affiliation. His affiliation information has been changed to include the Parker Institute for Cancer Immunotherapy in San Francisco, California. Accordingly, the affiliation information for Carl H June has been updated to distinguish the Parker Institute from the University of Pennsylvania; these are now two separate affiliations. All affiliation numbers have been revised. The error did not appear in the HTML and PDF versions of the article.
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